ArticleJournal of veterinary internal medicine2026
Retrospective evaluation of leflunomide as second-line immunosuppressive therapy in dogs with meningoencephalomyelitis of unknown origin: 18 cases (2018-2025).
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningoencephalomyelitis of unknown origin (MUO) comprises a group of noninfectious inflammatory diseases affecting the canine central nervous system. To date, no consensus exists regarding the optimal treatment. Leflunomide has been used as a second-line immunosuppressant, but clinical outcome data remain limited. HYPOTHESIS/
objectivesTo evaluate the clinical use, efficacy, and adverse effects of leflunomide with glucocorticoids in dogs with suspected MUO that required adjunctive therapy after initial glucocorticoid monotherapy. ANIMALS: Eighteen client-owned dogs with a presumptive diagnosis of MUO treated with leflunomide.
methodsRetrospective case series (2018-2025). Data included clinical signs, neurologic assessments, imaging and cerebrospinal fluid results, laboratory findings, treatment protocols, adverse effects, and survival. Treatment response was classified as complete, partial, or none using the neurodisability scale. Data analyses included descriptive statistics, Kaplan-Meier survival analysis, Cox proportional hazards models, and group comparisons applying Fisher's exact and Kruskal-Wallis tests.
resultsThe response rate to leflunomide was 66% (22% complete, 44% partial), and the estimated median survival following leflunomide initiation was 1277 days (95% CI, 194 days-not reached due to a low event rate), with 65% of dogs surviving at 1 year. Adverse effects occurred in 39% of dogs, most commonly mild signs of gastrointestinal disease or dysfunction (28%). CONCLUSIONS AND CLINICAL IMPORTANCE: Leflunomide appears to be a well-tolerated and potentially effective second-line treatment for dogs with suspected MUO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.